Chongqing Kangle Pharmaceutical Co.Ltd.

Chongqing Kangle Pharmaceutical Co., Ltd. was established in January 1988, located at No. 4 Huazhong Road, Changshou Economic and Technological Development Zone, Chongqing City, which is a national level park. It is controlled by Tongfang Pharmaceutical Group Co., Ltd.(its parent company is Huakong Kangtai Group Co., Ltd. listed on the main board of Hong Kong, stock code HK.01312) and belongs to Shanxi Construction Investment Group Co., Ltd. Shenzhen Huarongtai Asset Management Co., Ltd.

Kangle Pharma. is a R&D base for the production of APIs and pharmaceutical intermediates based on chemical synthesis. Products are exported to many regions of the world, widely recognized in the international pharmaceutical market, has a good reputation. The products of the company involved in antimalarial drugs, mental system drugs, antirheumatic drugs, cardiovascular drugs, anti-tumor drugs, andrology drugs, pharmaceutical intermediates, etc. The company has 258 employees, 25% of whom are professional technicians. The company is market-oriented and driven by technological innovation, vigorously promoting product exports and high-tech project research and development.

The company has obtained 6 key new products, 12 high-tech products, 2 technological innovation projects in Chongqing City, 2 scientific and technological breakthrough projects and 6 scientific and technological planning projects in Changshou District. The company has 151 patents, 91 invention patents, 60 utility model patents, 10 invention patents and 60 utility model patents; 2 third prizes for scientific and technological progress, 1 second prize for scientific and technological progress; 24 scientific and technological achievements registration. It was awarded as "Chongqing City Key Support Small and Medium-sized Enterprises," Innovation Fund "Star Cultivation Project," the first batch of "four-star" cultivation enterprises, advanced collectives in technological innovation, advanced collectives in scientific and technological work, demonstration production enterprises, outstanding innovation enterprises, intellectual property pilot units in Chongqing City, municipal intellectual property advantage enterprises and national high-tech enterprises. And the company is the teaching practice base of Tsinghua University, national intellectual property advantage enterprises.

The company has a complete quality management system, products obtained national drug registration approval and GMP certification, a number of products are qualified by the United States FDA, Japan PMDA and WHO PQ. And products are exported to the United States, Europe, Japan, South America, Southeast Asia and other countries or regions.

The Company has established a complete EHS management system and set up a full-time EHS management department. Obtained "Chongqing City Discharge Pollutant License,""Safety Production License,""Safety Standardization Enterprise" and other certificates. The company attaches importance to environmental protection, safety, occupational health and social responsibility, adheres to the people-oriented concept, and attaches importance to the health and safety of employees.Since its establishment, the company has not experienced any major quality, environmental or safety production liability accidents.

The company has formulated a sound financial management system, carried out enterprise financial management in accordance with national laws and regulations, established a benign cooperative relationship with banks, and has a good reputation.